Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1995-06-07
1997-11-04
Cunningham, Thomas M.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4241841, 435 693, 435 696, 435 711, 514 2, 514 12, 514 13, 530300, 530350, 530380, 530395, C07K 14705, A61K 3800
Patent
active
056836961
ABSTRACT:
gpD protein, the major subunit of the Duffy blood group antigenic system, has been isolated. gpD protein contains the receptor, by which P. vivax enters red cells and causes malaria. gpD has significant sequence homology with human and rabbit interleukin-8 receptors and, therefore, gpD protein likely is a new class of chemoattractant cytokines receptor. gpD protein cDNA has a quasi-total homology with a human hippocampus cDNA clone HHCMF86 and, therefore, gpD protein or a homologous protein may be present as a neuropeptide receptor in brain. gpD protein is present in all red cell progenitors and it may be a receptor for cell proliferation and/or differentiation. gpD protein cDNA identifies in human kidney a mRNA of the same size as the bone marrow. Since the kidney is not and has no potential to become an erythropoietic organ, this putative chemoattractant receptor may have essential renal functions. gpD protein has therapeutic value in the prevention of malaria and in the regulation of erythrocyte, neural and renal functions and can be combined with physiologically acceptable diluents to yield a therapeutic agent suitable for these purposes. Peptides corresponding to a portion of gpD protein that contains the receptor also have been synthesized. Such peptides have therapeutic usefulness identical to that of gpD protein. gpD protein and such peptides also have utility in the production of therapeutics, e.g., antibodies, complementary peptides, etc., which are also useful to treat malaria and regulate essential erythrocyte, neural and renal functions.
REFERENCES:
patent: 5198347 (1993-03-01), Miller et al.
patent: 5578670 (1996-11-01), Pogo et al.
Broome, S., et al., Biochemistry 75(6):2746-49 (Jun., 1978), "Immunological screening method to detect specific translation products".
Chaudhuri, A., et al., J. B.C. 264(23):13770-74 (1989), "Purification and characterization of an erythrocyte membrane protein complex carrying Duffy blood group antigenicity".
Chaudhuri, A., et al., Proc.Nat'l. Acad. Sci. 90:10793-97 (Nov., 1993), "Cloning of glycoprotein D cDNA, which encodes the major subunit of the Duffy blood group system and the receptor for the Plasmodium vivax malaria parasite".
Goodman, H. M., et al., Methods in Enzymology, vol. 68, pp. 75-90 (1979), "Cloning of hormone genes from a mixture of cDNA molecules".
Nichols, M. E., et al., J. Exp. Med. 166:776-785 (Sep., 1988), "A new human Duffy blood group specificity defined by a murine monoclonal antibody".
Chaudhuri Asok
Pogo Angel Oscar
Cunningham Thomas M.
New York Blood Center Inc.
LandOfFree
Cloning of duffy blood group antigen, gpD does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cloning of duffy blood group antigen, gpD, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cloning of duffy blood group antigen, gpD will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1830954